Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News aTyr Pharma Inc ATYR

Healthcare Biotechnology
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more

Recent & Breaking News (NDAQ:ATYR)

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT(TM) Clinical Trial Participants

GlobeNewswire February 21, 2024

aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity

GlobeNewswire January 29, 2024

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

GlobeNewswire January 18, 2024

aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023

GlobeNewswire November 13, 2023

aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update

GlobeNewswire November 9, 2023

aTyr Pharma to Present at November Investor Conferences

GlobeNewswire November 1, 2023

aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT(TM) Study of Efzofitimod in Patients with SSc-ILD

GlobeNewswire October 31, 2023

aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes

GlobeNewswire September 11, 2023

aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire August 24, 2023

aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update

GlobeNewswire August 9, 2023

European Commission Grants Orphan Drug Designation for aTyr Pharma's Efzofitimod for Treatment of Systemic Sclerosis

GlobeNewswire June 22, 2023

aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference

GlobeNewswire June 20, 2023

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 9, 2023

aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)

GlobeNewswire June 6, 2023

aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference

GlobeNewswire May 25, 2023

aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference

GlobeNewswire May 22, 2023

aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 11, 2023

aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update

GlobeNewswire May 9, 2023

aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting

GlobeNewswire April 17, 2023

aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases

GlobeNewswire March 30, 2023